Table 3.

Multivariable logistic regression for parameters associated with significant renal impairment (eGFR < 60 mL min⁻¹ 1.73 m⁻²) and severely impaired renal function (eGFR < 30 mL min⁻¹ 1.73 m⁻²)

	Multivariable analysis for significant renal impairment (<60 mL min−1 1.73 m−2)		Multivariable analysis for severe renal impairment (<30 mL min−1 1.73 m−2)
	OR (95% CI)	P value	OR (95% CI)	P value
Patient demographics and comorbidities
Age, years	1.034 (1.021–1.047)	<0.001	1.001 (0.981–1.022)	0.914
Diabetes mellitus	1.922 (1.342–2.752)	<0.001	3.860 (2.352–6.336)	<0.001
Hypertension	1.372 (0.913–2.063)	0.128	2.518 (1.114–5.691)	0.026
ACEi/ARB use	0.917 (0.664–1.265)	0.597	0.412 (0.245–0.691)	<0.001
Diuretic use	2.339 (1.696–3.226)	<0.001	2.157 (1.164–3.997)	0.015
Aldosterone antagonist	1.266 (0.875–1.831)	0.211	0.656 (0.361–1.191)	0.166
Echocardiographic variables
LV EDV, mL	1.004 (1.002–1.006)	0.001	1.004 (1.000–1.007)	0.028
LVEF, %	0.994 (0.984–1.005)	0.288	1.016 (0.998–1.034)	0.075
Significant MR	1.137 (0.827–1.564)	0.428	1.390 (0.834–2.317)	0.206
RV EDA, mm2	1.009 (0.995–1.024)	0.189	0.997 (0.969–1.025)	0.811
TA diameter, mm	0.997 (0.976–1.017)	0.739	0.985 (0.950–1.022)	0.433
TR RVol, mL	1.000 (0.997–1.003)	0.998	1.002 (0.998–1.007)	0.271
TAPSE, mm	0.963 (0.935–0.992)	0.012	0.944 (0.893–0.997)	0.038
Estimated RAP, mmHg	0.978 (0.947–1.010)	0.174	1.014 (0.961–1.070)	0.605
PASP, mmHg	1.006 (0.997–1.015)	0.217	1.001 (0.987–1.016)	0.854

ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; EDA, end‐diastolic area; EDV, end‐diastolic volume; EF, ejection fraction; eRAP, estimated right atrial pressure; LV, left ventricle; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; PASP, pulmonary artery systolic pressure; RV, right ventricle; RVol, regurgitant volume; TA, tricuspid annulus; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation.